TY - JOUR
T1 - Boron’s journey
T2 - advances in the study and application of pharmacokinetics
AU - Ocampo-Néstor, Ana L.
AU - Trujillo-Ferrara, José G.
AU - Abad-García, Antonio
AU - Reyes-López, Cynthia
AU - Geninatti-Crich, Simonetta
AU - Soriano-Ursúa, Marvin A.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Introduction: Boron-containing compounds (BCCs) are attractive chemical entities in drug development. Some of these compounds have been used in the treatment of human disease, and studies on their pharmacodynamics suggest that they employ multiple forms of activity. However, less is known about the pharmacokinetic profile of these molecules. Areas covered: The herein compiled reported data is presented in accordance with the classical ‘ADME’ system for identifying the scope of BCCs in the respective fields. Our analysis suggests that these compounds have several distinct ways to move within the human body, and that the specific structural features of each molecule account for its distinct pharmacokinetic profile. These insights should be useful for designing BCCs with a desired effect. Expert opinion: Increasing knowledge about the pharmacokinetics of BCCs is providing a broader understanding about the design of new release systems and potential drugs, as well as probable protein transporters that could be related to key roles in physiological processes. These transporters may be involved in sodium transport, hormone release and regulation of the cell cycle. The shared features among groups of BCCs are being identified in order to apply these insights to the design of advantageous compounds.
AB - Introduction: Boron-containing compounds (BCCs) are attractive chemical entities in drug development. Some of these compounds have been used in the treatment of human disease, and studies on their pharmacodynamics suggest that they employ multiple forms of activity. However, less is known about the pharmacokinetic profile of these molecules. Areas covered: The herein compiled reported data is presented in accordance with the classical ‘ADME’ system for identifying the scope of BCCs in the respective fields. Our analysis suggests that these compounds have several distinct ways to move within the human body, and that the specific structural features of each molecule account for its distinct pharmacokinetic profile. These insights should be useful for designing BCCs with a desired effect. Expert opinion: Increasing knowledge about the pharmacokinetics of BCCs is providing a broader understanding about the design of new release systems and potential drugs, as well as probable protein transporters that could be related to key roles in physiological processes. These transporters may be involved in sodium transport, hormone release and regulation of the cell cycle. The shared features among groups of BCCs are being identified in order to apply these insights to the design of advantageous compounds.
KW - Boron
KW - bioavailability
KW - biotransformation
KW - pharmacokinetics
KW - releasing system
UR - http://www.scopus.com/inward/record.url?scp=85009230837&partnerID=8YFLogxK
U2 - 10.1080/13543776.2017.1252750
DO - 10.1080/13543776.2017.1252750
M3 - Artículo de revisión
C2 - 27788608
AN - SCOPUS:85009230837
SN - 1354-3776
VL - 27
SP - 203
EP - 215
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 2
ER -